San Francisco, United States
FibroGen, Inc., founded in 1993, is a United States-based company operating in the biopharma and biotechnology sectors. The company is dedicated to pioneering first-in-class therapeutics targeting significant unmet medical needs globally, with a focus on areas such as anemia, fibrotic disease, and cancer.
Leveraging their expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology, FibroGen is advancing innovative treatments like Pamrevlumab, currently in clinical trials for pancreatic cancer and Duchenne muscular dystrophy, and Roxadustat, an approved oral medication for anemia of chronic kidney disease.
In addition to its established portfolio, the company is expanding into immuno-oncology and autoimmune research. Despite being a mature entity with its last investment as a Post-IPO Equity investment on 14 August 2017, FibroGen continues to be a dynamic player with substantial potential for impacting global health through its extensive R&D pipelines and commitment to innovation where "people and science thrive."
